Burrill Life Science Capital Fund IV, a new $500 million life sciences investment fund to be managed by Burrill & Company, will get a $200 million capital investment from the Russian nanotechnology investment company RUSNANO. This is the largest equity capital investment commitment by a Russian company in a U.S. private equity fund.
San Francisco-based Burrill & Company is a life sciences merchant bank focused exclusively on companies involved in biotechnology, pharmaceuticals, diagnostics, devices, human healthcare and related medical technologies, nutraceuticals and wellness, agricultural biotechnology, and industrial biotechnology (biomaterials and bioprocesses).
Burrill Life Sciences Capital Fund III, of which Burrill & Company is the general partner, was capitalized at $283 million in 2006.
RUSNANO recently invested in ItN Nanovation of Germany and Crocus Technology of France.